| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we revealed that the PDE3 inhibitor cilostazol improved the impaired learning and memory function in aged C57BL/6J mice and senescence-accelerated mouse prone 8 (SAMP8) to the same extent as young mice. Based on these findings, a clinical trial is now underway in Japan to gain approval for the use of cilostazol in treating mild cognitive impairment.
In addition, sub-effective dose of cilostazol and donepezil in combination enhances learning and memory function in aged C57BL/6J mice. These results suggest that the combination therapy comprising two or more drugs may offer a new pharmacological approach for treating cognitive disorders, as the combination therapy demonstrated to be an effective strategy for treating some types of diseases.
|
